This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Isis Pharmaceuticals, Inc. (ISIS)
Review KYNAMRO Data Presented at the ESC 2012 Meeting Conference Transcript
August 29, 2012 10:00 AM ET
Dr. Stanley Crooke - Chairman and CEO
Dr. Klaus Parhofer - Professor, Metabolism and Endocrinology, Ludwig-Maximilians University, Munich
Lynne Parshall - Chief Operating Officer
Rich Geary - Senior Vice President, Development
Walter Singleton - Vice President, Development and CMO
Wade Walke - Executive Director, Corporate Communications and IR
Nicholas Bishop - Cowen & Company
Stephen Willey - Stifel Nicolaus
Carol Werther - Summer Street
Chad Messer - Needham & Company
Sam Colin - First Manhattan Company
Good day, ladies and gentlemen. And welcome to Isis Pharmaceuticals' Conference Call to Review KYNAMRO Data that was recently presented at the ESC 2012 Meeting. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the conference over to Dr. Stanley Crooke, Chairman and CEO. Please proceed.
Dr. Stanley Crooke
Good morning, everyone. And thanks for joining us today. As [Donato] indicated the purpose of this call is to have Dr. Parhofer to review the additional results or some additional results on KYNAMRO that were presented at the European Society of Cardiology Meeting this morning in Munich.
Joining us on today’s call are Dr. Klaus Parhofer, Professor of Metabolism and Endocrinology at Ludwig-Maximilians University in Munich; Lynne Parshall, Chief Operating Officer; Rich Geary, Senior Vice President of Development; Walter Singleton, Vice President, Development and Chief Medical Officer; and Wade Walke, Executive Director, Corporate Communications and Investor Relations.